Takeda Targets Diverse Representation in Phase III Psoriasis Trials Led by LaShell Robinson

Takeda is implementing strategies to improve representation in clinical trials, with a focus on Phase III psoriasis studies. LaShell Robinson, who leads global feasibility and trial equity at the company, is overseeing these efforts. The initiatives aim to address the persistent issue of underrepresentation of diverse populations in clinical research. Robinson’s work involves identifying and mitigating barriers that prevent diverse patient populations from participating in clinical trials. These barriers can include factors such as lack of awareness, geographical limitations, language difficulties, and distrust in the medical system. Takeda is working to overcome these obstacles through targeted outreach programs, community partnerships, and culturally sensitive communication strategies. In the specific context of Phase III psoriasis trials, the company is focusing on ensuring that recruitment efforts reach a diverse range of patients affected by the condition. The goal is to generate clinical trial data that accurately reflects the safety and efficacy of treatments across different demographic groups, ultimately leading to more equitable healthcare outcomes.

Newsflash | Powered by GeneOnline AI
Date: April 7, 2025

Author

Mark Chiang